Cangrelor Can’t Escape Its Past At FDA Advisory Committee
This article was originally published in The Pink Sheet Daily
Executive Summary
The Medicines Co.’s anti-clotting drug had one relatively positive study, but two failed ones, and that produced two lopsided “no” votes by the Cardiovascular and Renal Drugs Advisory Committee.
You may also be interested in...
Medicines Co. Gains Kengreal Approval; Can It Alter Clinical Practice Too?
Antiplatelet's indication is narrow, but TMC hopes to leverage cultural changes in 'door-to-procedure' times.
Cangrelor Survives Second Advisory Committee, But Narrowly
FDA panel members were not enthusiastic about the antiplatelet, but felt it could help ‘some people.’
Cangrelor’s Second Advisory Committee Could Be The Charm
FDA reviewers again recommended approval of the antiplatelet, but this time there doesn’t appear to be opposition from the team leader.